Massachusetts is currently home to 3205 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in MTNBC
NCT06351332
Recruiting
This research is being done to evaluate the safety and effectiveness of a drug currently known as Azenosertib (ZN-C3) in combination with the drugs carboplatin and pembrolizumab in metastatic triple-negative breast cancer. The names of the study drugs involved in this study are: * Azenosertib (a type of WEE1 inhibitor) * Carboplatin (a type of platinum compound) * Pembrolizumab (a type of monoclonal antibody)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Breast Cancer, Breast Cancer Female, Triple Negative Breast Cancer, Hormone Receptor Negative Malignant Tumor Breast Triple, HER2-negative Breast Cancer
Register for Updates
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
NCT06136728
Recruiting
The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment alone. The main questions this study will answer are: * Does combining dalfampridine with physical therapy improve mobility more than physical therapy without concurrent dalfampridine? * Is the combined treatment associated with better outcomes than the medication (dalfa... Read More
Gender:
ALL
Ages:
Between 25 years and 75 years
Trial Updated:
12/16/2024
Locations: MGH Institute of Health Professions, Boston, Massachusetts
Conditions: Multiple Sclerosis
Register for Updates
A Study of Sovilnesib in Subjects with Ovarian Cancer
NCT06084416
Recruiting
This is a randomized, phase 1b study to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of sovilnesib at different dose levels to establish the Recommended Phase 2 Dose (RP2D) of sovilnesib in subjects with high grade serous ovarian cancer (HGSOC).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Chromosomal Instability
Register for Updates
Letrozole in Uterine Leiomyosarcoma
NCT05649956
Recruiting
This is a clinical trial to test letrozole in patients with uterine leiomyosarcoma. The main question is will treatment with letrozole extend progression-free survival in patients. Patients will receive 2/5 mg of letrozole daily.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: University of Massachusetts Memorial Medical Center, Worcester, Massachusetts
Conditions: Uterine Leiomyosarcoma
Register for Updates
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
NCT05184335
Recruiting
This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily over 4 weeks, then in the long-term flexible doses 15-50mg daily over a period of 52 weeks.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/16/2024
Locations: Reviva site, Boston, Massachusetts
Conditions: Schizophrenia
Register for Updates
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
NCT04831580
Recruiting
This is a randomized controlled trial to compare survival for patients who undergoe robotic assisted laparoscopy versus open hysterectomy and lymph node assessment for the treatment of early stage cervical cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Baystate Medical Center, Springfield, Massachusetts
Conditions: Cervical Cancer
Register for Updates
Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens
NCT04821141
Recruiting
Women at risk for development of breast cancer and experiencing vasomotor menopausal symptoms (hot flashes) will be randomized to bazedoxifene (BZA) plus conjugated estrogens (CE) for 6 months versus a wait list control. Two risk factors for development of breast cancer will be studied pre-study and after 6 months: fibroglandular volume (FGV) on mammogram as assessed by Volpara software and proliferation by Ki-67 immunocytochemistry in benign breast tissue acquired by random periareolar fine nee... Read More
Gender:
FEMALE
Ages:
Between 45 years and 64 years
Trial Updated:
12/16/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Risk Reduction, Breast Cancer
Register for Updates
Refining Local-Regional Therapy for IBC
NCT04636710
Recruiting
This Feasibility study is trying to determine: * If Lymphoscintigraphy (imaging of the lymphatic drainage patterns) is effective in demonstrating the drainage to the sentinel lymph nodes in patients with inflammatory breast cancer. * The likelihood of identifying the sentinel lymph nodes in the operating room, using both blue dye and the radioactive substance used for lymphoscintigraphy. * The incidence of lymphedema (arm swelling which occurs after lymph node surgery) in women with inflammator... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Breast Cancer, Inflammatory Breast Cancer, Sentinel Lymph Node
Register for Updates
Effects of Ketosis on Brain Function in Patients With T1DM
NCT04219709
Recruiting
The scientific goal of this study is to examine the effects of a ketogenic diet on hypoglycemia tolerance and brain function in people with type 1 diabetes mellitus (T1D) and to clarify the mechanistic role of ketones in this process. Glycemic management of T1D is typified by alternating periods of hyper- and hypo-glycemia. Because brain metabolism under usual conditions depends on glucose, acute hypoglycemia leads to immediate complications including impaired cognitive function and a counter-re... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
12/16/2024
Locations: Boston Childrens Hospital, Boston, Massachusetts
Conditions: Type1diabetes
Register for Updates
Very Low Carbohydrate Diets and Glucagon Response in T1DM
NCT04200391
Recruiting
Despite major technological advances, management of type one diabetes mellitus (T1D) remains suboptimal, putting millions of people at risk for immediate and long-term complications. After meals, a mismatch between carbohydrate absorption rate and insulin action typically leads to alternating periods of hyper- and hypoglycemia. A conceptually promising approach to control both problems is dietary carbohydrate restriction to reduce postprandial blood glucose changes and insulin needs. In a prior... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
12/16/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Type1diabetes
Register for Updates
Type 1 Diabetes Management Using a Very Low Carbohydrate Versus Standard Diet
NCT03710928
Recruiting
Despite major technological advances, management of type one diabetes mellitus (T1D) remains suboptimal, putting millions of people at risk for immediate and long-term complications. After meals, a mismatch between carbohydrate absorption rate and insulin action typically leads to alternating periods of hyper- and hypoglycemia. A conceptually promising approach to control both problems is dietary carbohydrate restriction to reduce postprandial blood glucose changes and insulin needs. In a prior... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
12/16/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Type1diabetes
Register for Updates
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
NCT02744677
Recruiting
This study will demonstrate the safety and effectiveness of the Edwards Lifesciences SAPIEN 3/SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve (THV) Systems in subjects with a dysfunctional right ventricular outflow tract (RVOT) conduit or previously implanted valve in the pulmonic position with a clinical indication for intervention.
Gender:
ALL
Ages:
All
Trial Updated:
12/16/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration
Register for Updates